IL1B and macrophage activation syndrome: Within the prospective nationwide cohort starting anakinra as first‐line monotherapy, the incidence rate of MAS in the first two years of disease was 18% (12 of 66 patients, with 11 of 12 while receiving IL‐1 inhibition).